|
110 Companies |
|
139 Products |
|
139 Products |
|
95 Mechanisms of Action |
|
2 Trials |
|
919 News |
|
| «12345678910111213...1819» |
- ||||||| Xeljanz (tofacitinib) / Pfizer
Clinical: OPAL BEYOND: Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors (clinicaltrials.gov) - Apr 18, 2016
P3, N=396, Completed, Sponsor: Pfizer
Active, not recruiting --> Completed
- ||||||| Xeljanz (tofacitinib) / Pfizer
Clinical: OPAL BROADEN: Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study (clinicaltrials.gov) - Apr 15, 2016
P3, N=422, Completed, Sponsor: Pfizer
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Humira (adalimumab) / Eisai, AbbVie
Enrollment change, Trial primary completion date, Real-world evidence, Real-world: Concomitant Longitudinal Evaluation of Adalimumab With Methotrexate in the Real World: the CLEAR Study (clinicaltrials.gov) - Apr 15, 2016
P3, N=50, Recruiting, Sponsor: AbbVie
Active, not recruiting --> Completed N=200 --> 50 | Trial primary completion date: Oct 2017 --> Jun 2017
- Orencia (abatacept) / BMS, Stelara (ustekinumab) / J&J
Enrollment closed, Enrollment change: Efficacy of Ustekinumab Followed by Abatacept for the Treatment of Psoriasis Vulgaris (clinicaltrials.gov) - Apr 14, 2016
P2, N=108, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
N=200 --> 50 | Trial primary completion date: Oct 2017 --> Jun 2017 Recruiting --> Active, not recruiting | N=140 --> 108
- ||| Trial completion: To Observe the Impacts of Anti-Tumor Necrosis Factor (TNF) Effectiveness on Improvement in Work Place and Household Productivity for Patients With Psoriatic Arthritis (PsA) (clinicaltrials.gov) - Apr 8, 2016
P=N/A, N=125, Completed, Sponsor: AbbVie
Recruiting --> Active, not recruiting | N=140 --> 108 Active, not recruiting --> Completed
- Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
Trial completion, Enrollment change: Use of Botulinum Toxin to Treat Psoriasis (clinicaltrials.gov) - Apr 4, 2016
P1, N=8, Completed, Sponsor: University of Minnesota - Clinical and Translational Science Institute
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=10 --> 8
- Enrollment open, Trial primary completion date, IO biomarker: Effects of Subcutaneous Hyaluronidase Administration on Psoriatic Plaques (clinicaltrials.gov) - Apr 1, 2016
P2, N=10, Recruiting, Sponsor: Tissa Hata, MD
Active, not recruiting --> Completed | N=10 --> 8 Not yet recruiting --> Recruiting | Trial primary completion date: Jul 2016 --> Jul 2017
- Enrollment change, Trial termination: MMAPPS: Monitoring and Modifying Atherosclerosis in Psoriasis Patients Study (clinicaltrials.gov) - Mar 23, 2016
P=N/A, N=29, Terminated, Sponsor: Massachusetts General Hospital
Not yet recruiting --> Recruiting | Trial primary completion date: Jul 2016 --> Jul 2017 N=50 --> 29 | Recruiting --> Terminated
- |||| Enbrel (etanercept) / Pfizer, Amgen
Trial primary completion date: Pediatric Open-Label Extension Study of Etanercept in Patients With Plaque Psoriasis (clinicaltrials.gov) - Mar 23, 2016
P3, N=182, Active, not recruiting, Sponsor: Amgen
N=50 --> 29 | Recruiting --> Terminated Trial primary completion date: Nov 2019 --> Dec 2017
- |||| Xeljanz (tofacitinib) / Pfizer
Clinical: A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis (clinicaltrials.gov) - Mar 14, 2016
P3, N=3200, Recruiting, Sponsor: Pfizer
Trial primary completion date: Nov 2019 --> Dec 2017 Trial primary completion date: Feb 2018 --> May 2016
- | Trial completion, Enrollment change, Trial primary completion date: Photocil (Topical) for the Treatment of Psoriasis Vulgaris (clinicaltrials.gov) - Mar 11, 2016
P=N/A, N=12, Completed, Sponsor: Applied Biology, Inc.
Trial primary completion date: Feb 2018 --> May 2016 Recruiting --> Completed | N=50 --> 12 | Trial primary completion date: Jul 2014 --> Dec 2014
- ||| Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J
Review, Trial initiation date, Trial primary completion date: Analysis of Birth Outcomes of Swedish, Danish and Finnish Women Exposed to Remicade With Inflammatory Bowel Disease, Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Psoriasis (clinicaltrials.gov) - Mar 10, 2016
P4, N=370, Active, not recruiting, Sponsor: Janssen Biotech, Inc.
Recruiting --> Completed | N=50 --> 12 | Trial primary completion date: Jul 2014 --> Dec 2014 Initiation date: Oct 2006 --> Jan 2007 | Trial primary completion date: Jan 2016 --> Dec 2017
- Enrollment change, Trial termination, Patient reported outcomes: Post Marketing Observational Study on Venezuelan Patients With Psoriasis (clinicaltrials.gov) - Mar 8, 2016
P=N/A, N=10, Terminated, Sponsor: AbbVie (prior sponsor, Abbott)
Initiation date: Oct 2006 --> Jan 2007 | Trial primary completion date: Jan 2016 --> Dec 2017 N=100 --> 10 | Suspended --> Terminated
- ||| brepocitinib (PF-06700841) / Pfizer
PK/PD data: A Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06700841, With Bioavailability/Food Effect Investigation (clinicaltrials.gov) - Mar 4, 2016
P1, N=96, Completed, Sponsor: Pfizer
N=100 --> 10 | Suspended --> Terminated Recruiting --> Completed
- |||| Enbrel (etanercept) / Pfizer, Amgen
Trial completion: REPArE: Rating Evaluations in Psoriatic Arthritis (PsA) With Etanercept (Enbrel®) (clinicaltrials.gov) - Feb 27, 2016
P4, N=110, Completed, Sponsor: Amgen
Recruiting --> Completed Active, not recruiting --> Completed
- ||||||| Enbrel (etanercept) / Pfizer, Amgen
Trial completion: Study of Etanercept in the Treatment of Psoriasis in Adult Subjects (clinicaltrials.gov) - Feb 27, 2016
P3, N=391, Completed, Sponsor: Amgen
Active, not recruiting --> Completed No longer recruiting --> Completed
- ||||||| Enbrel (etanercept) / Pfizer, Amgen
Trial completion: Evaluating the Safety of Etanercept 50 mg Twice Weekly in Subjects With Psoriasis (clinicaltrials.gov) - Feb 27, 2016
P3, N=600, Completed, Sponsor: Amgen
No longer recruiting --> Completed No longer recruiting --> Completed
- ||||||| Enbrel (etanercept) / Pfizer, Amgen
Trial completion: Evaluating the Safety of Etanercept in the Treatment of Psoriasis in Adult Subjects (clinicaltrials.gov) - Feb 27, 2016
P3, N=912, Completed, Sponsor: Amgen
No longer recruiting --> Completed No longer recruiting --> Completed
- |||| Enbrel (etanercept) / Pfizer, Amgen
Trial completion, Combination therapy: Utilization of Narrow Band Ultraviolet B (UVB) Light Therapy and Etanercept for the Treatment of Psoriasis (clinicaltrials.gov) - Feb 27, 2016
P4, N=86, Completed, Sponsor: Amgen
No longer recruiting --> Completed Active, not recruiting --> Completed
- |||| Raptiva (efalizumab) / Roche, EMD Serono, Xoma
Trial completion, Combination therapy: A Study to Evaluate Raptiva in Combination With Topical Psoriasis Therapies (clinicaltrials.gov) - Feb 27, 2016
P4, N=300, Completed, Sponsor: Genentech, Inc.
Active, not recruiting --> Completed No longer recruiting --> Completed
- ||||||| Raptiva (efalizumab) / Roche, EMD Serono, Xoma
Trial completion: A Study to Evaluate the Safety of Raptiva in Adults With Plaque Psoriasis Previously Enrolled in Study ACD2600g (clinicaltrials.gov) - Feb 27, 2016
P3, N=450, Completed, Sponsor: Genentech, Inc.
No longer recruiting --> Completed No longer recruiting --> Completed
- ||||||| Remicade (infliximab) / J&J
Trial completion: A Study of the Safety and Efficacy of Infliximab in Patients With Psoriasis (clinicaltrials.gov) - Feb 27, 2016
P3, N=378, Completed, Sponsor: Centocor, Inc.
No longer recruiting --> Completed No longer recruiting --> Completed
- |||| Humira (adalimumab) / Eisai, AbbVie
Trial completion: Trial on the Effect of Adalimumab on Vascular Inflammation in Patients With Psoriasis (clinicaltrials.gov) - Feb 24, 2016
P4, N=107, Completed, Sponsor: Innovaderm Research Inc.
No longer recruiting --> Completed Active, not recruiting --> Completed
- ||| Humira (adalimumab) / AbbVie
Enrollment closed: Adalimumab-psoriasis and Small Bowel Lesions (clinicaltrials.gov) - Feb 23, 2016
P4, N=100, Active, not recruiting, Sponsor: Innovaderm Research Inc.
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||| remtolumab (ABT-122) / AbbVie
Enrollment closed, P2 data, Trial initiation date: A Phase 2 Study to Investigate the Safety, Tolerability and Efficacy of ABT-122 in Subjects With Active Psoriatic Arthritis (PsA) Who Have an Inadequate Response to Methotrexate (MTX) (clinicaltrials.gov) - Feb 21, 2016
P2, N=220, Active, not recruiting, Sponsor: AbbVie
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Initiation date: Jan 2015 --> Apr 2015
- anti-TNF/IL-17A FynomAb (COVA322) / J&J
Enrollment change, Trial termination: Safety and Tolerability Study of COVA322 in Patients With Stable Chronic Moderate-to-severe Plaque Psoriasis (clinicaltrials.gov) - Feb 17, 2016
P1/2, N=24, Terminated, Sponsor: Covagen
Recruiting --> Active, not recruiting | Initiation date: Jan 2015 --> Apr 2015 N=39 --> 24 | Recruiting --> Terminated; Based on the observed safety profile of COVA322, the sponsor decided to stop the clinical study.
- ||||| Simponi (golimumab) / Merck (MSD), Mitsubishi Tanabe, J&J
Enrollment closed: A Study of Golimumab in Participants With Active Psoriatic Arthritis (clinicaltrials.gov) - Feb 11, 2016
P3, N=480, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
N=39 --> 24 | Recruiting --> Terminated; Based on the observed safety profile of COVA322, the sponsor decided to stop the clinical study. Recruiting --> Active, not recruiting
- Biomarker, Trial primary completion date: Serum Lipid Levels and Other Biomarkers of Cardiovascular Disease in Patients With Psoriasis (clinicaltrials.gov) - Feb 11, 2016
P=N/A, N=200, Recruiting, Sponsor: George Washington University
Recruiting --> Active, not recruiting Trial primary completion date: Nov 2015 --> Mar 2016
- Trial primary completion date: A Case Control Study Evaluating the Prevalence of Non-Alcoholic Fatty Liver Disease Among Patients With Psoriasis (clinicaltrials.gov) - Feb 11, 2016
P=N/A, N=370, Recruiting, Sponsor: George Washington University
Trial primary completion date: Nov 2015 --> Mar 2016 Trial primary completion date: Nov 2015 --> Jun 2016
- Trial primary completion date: Clinical Trial of PSORI-CM01（YXBCM01） Granule to Treat Stable Plaque Psoriasis (clinicaltrials.gov) - Feb 10, 2016
P=N/A, N=35, Terminated, Sponsor: Guangdong Provincial Hospital of Traditional Chinese Medicine
Trial primary completion date: Nov 2015 --> Jun 2016 Trial primary completion date: Aug 2015 --> Nov 2014
- |||| Enbrel (etanercept) / Pfizer, Amgen
Trial completion, Trial primary completion date: Study to Assess the Immunogenicity and Safety of Etanercept Produced in Plaque Psoriasis (clinicaltrials.gov) - Feb 10, 2016
P4, N=132, Completed, Sponsor: Amgen
Trial primary completion date: Aug 2015 --> Nov 2014 Active, not recruiting --> Completed | Trial primary completion date: Jul 2016 --> Nov 2015
- ||||| dimethyl fumarate controlled release (FP 187) / Forward Pharma
Trial initiation date, Head-to-Head: Efficacy Study on Dimethyl Fumarate to Treat Moderate to Severe Plaque Psoriasis (clinicaltrials.gov) - Feb 4, 2016
P3, N=500, Not yet recruiting, Sponsor: Forward-Pharma GmbH
Active, not recruiting --> Completed | Trial primary completion date: Jul 2016 --> Nov 2015 Initiation date: Jun 2015 --> Jun 2016
- | neihulizumab (ALTB-168) / AltruBio
Trial completion: A Phase II Study Evaluating the Efficacy and Safety of AbGn-168H in Patients With Active Psoriatic Arthritis (clinicaltrials.gov) - Jan 29, 2016
P2, N=20, Completed, Sponsor: AbGenomics B.V Taiwan Branch
Initiation date: Jun 2015 --> Jun 2016 Active, not recruiting --> Completed
- || Humira (adalimumab) / Eisai, AbbVie
Enrollment closed, Observational data: SPACTIVE: Study in Ankylosing Spondylitis (AS) and Psoriatic Arthritis (PsA) Patients to Evaluate Work Productivity Before and After the Start of Adalimumab Therapy in Daily Practice in Belgium (clinicaltrials.gov) - Jan 27, 2016
P=N/A, N=200, Active, not recruiting, Sponsor: AbbVie
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||| remtolumab (ABT-122) / AbbVie
P2 data, Trial initiation date: A Phase 2 Study to Investigate the Safety, Tolerability and Efficacy of ABT-122 in Subjects With Active Psoriatic Arthritis (PsA) Who Have an Inadequate Response to Methotrexate (MTX) (clinicaltrials.gov) - Jan 26, 2016
P2, N=220, Recruiting, Sponsor: AbbVie
Recruiting --> Active, not recruiting Initiation date: Apr 2015 --> Jan 2015
- |||| Humira (adalimumab) / Eisai, AbbVie
Trial primary completion date: A Study to Evaluate the Safety and Efficacy of Adalimumab in Subjects With Chronic Plaque Psoriasis and Nail Psoriasis (clinicaltrials.gov) - Jan 22, 2016
P3, N=200, Active, not recruiting, Sponsor: AbbVie
Initiation date: Apr 2015 --> Jan 2015 Trial primary completion date: Feb 2016 --> Oct 2015
- | Cimzia (certolizumab pegol) / Astellas, UCB
Trial completion: CRADLE: A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers (clinicaltrials.gov) - Jan 20, 2016
P1, N=17, Completed, Sponsor: UCB BIOSCIENCES, Inc.
Trial primary completion date: Feb 2016 --> Oct 2015 Active, not recruiting --> Completed
- ||||| Xeljanz (tofacitinib) / Pfizer
Clinical: OPAL BROADEN: Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study (clinicaltrials.gov) - Jan 15, 2016
P3, N=400, Active, not recruiting, Sponsor: Pfizer
Active, not recruiting --> Completed Completed --> Active, not recruiting
- ||||| Cosentyx (secukinumab) / Novartis
Enrollment closed: Extension Study of Secukinumab Prefilled Syringes in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III Studies With Secukinumab (clinicaltrials.gov) - Jan 7, 2016
P3, N=1150, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Completed --> Active, not recruiting Recruiting --> Active, not recruiting
- ||||||| Xeljanz (tofacitinib) / Pfizer
Clinical: OPAL BROADEN: Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study (clinicaltrials.gov) - Jan 6, 2016
P3, N=424, Completed, Sponsor: Pfizer
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Enrollment closed, Enrollment change, Trial primary completion date: Reduction of Pain Caused by Biologic Drugs in Psoriasis (clinicaltrials.gov) - Dec 30, 2015
P=N/A, N=124, Active, not recruiting, Sponsor: Icahn School of Medicine at Mount Sinai
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | N=200 --> 124 | Trial primary completion date: Dec 2015 --> Mar 2016
- Trial primary completion date: Premature Coronary Artery Disease (CAD) in Severe Psoriasis (clinicaltrials.gov) - Dec 23, 2015
P1, N=120, Active, not recruiting, Sponsor: University of Michigan
Recruiting --> Active, not recruiting | N=200 --> 124 | Trial primary completion date: Dec 2015 --> Mar 2016 Trial primary completion date: Oct 2015 --> Mar 2016
- ||| Trial completion, Enrollment change, Trial primary completion date: Cardiovascular Risk Assessment in Patients With Severe Psoriasis Treated With Biologic Agents (clinicaltrials.gov) - Dec 21, 2015
P=N/A, N=126, Completed, Sponsor: University of Aarhus
Trial primary completion date: Oct 2015 --> Mar 2016 Active, not recruiting --> Completed | N=90 --> 126 | Trial primary completion date: Jul 2014 --> Sep 2015
- ||||| Simponi (golimumab) / Merck (MSD), Mitsubishi Tanabe, J&J
Trial initiation date: A Study of Golimumab in Participants With Active Psoriatic Arthritis (clinicaltrials.gov) - Dec 21, 2015
P3, N=440, Recruiting, Sponsor: Janssen Research & Development, LLC
Active, not recruiting --> Completed | N=90 --> 126 | Trial primary completion date: Jul 2014 --> Sep 2015 Initiation date: Apr 2014 --> Sep 2014
- Enrollment change, Trial termination: Pilot Study Characterizing Adipose Tissue Leukocytes by Flow Cytometry/Microscopy in Lean, Obese and Psoriatic Subjects (clinicaltrials.gov) - Dec 21, 2015
P=N/A, N=1, Terminated, Sponsor: Rockefeller University
Initiation date: Apr 2014 --> Sep 2014 N=43 --> 1 | Recruiting --> Terminated; Low enrollment
- Trial completion, Trial primary completion date: Use of Localized NB-UVB (Levia®) in the Treatment of Plaque-psoriasis (clinicaltrials.gov) - Dec 17, 2015
P4, N=21, Completed, Sponsor: Tufts Medical Center
N=43 --> 1 | Recruiting --> Terminated; Low enrollment Recruiting --> Completed | Trial primary completion date: Sep 2014 --> Dec 2014
- trichuris suis ova (CNDO-201) / Fortress
Enrollment change, Trial termination, Trial primary completion date: Efficacy Study of Trichuris Suis Ova to Treat Chronic Plaque Psoriasis (clinicaltrials.gov) - Dec 17, 2015
P1, N=3, Terminated, Sponsor: Tufts Medical Center
Recruiting --> Completed | Trial primary completion date: Sep 2014 --> Dec 2014 N=12 --> 3 | Recruiting --> Terminated | Trial primary completion date: Jan 2015 --> Sep 2014; lack of efficacy
- |||| Trial completion: EPIDEPSO: Clinical Assessment and Psychosocial Impact of Psoriasis (clinicaltrials.gov) - Dec 15, 2015
P4, N=719, Completed, Sponsor: Janssen Pharmaceutica N.V., Belgium
N=12 --> 3 | Recruiting --> Terminated | Trial primary completion date: Jan 2015 --> Sep 2014; lack of efficacy Active, not recruiting --> Completed
- || Enrollment closed: Observational Study to Estimate the Effectiveness of Biologics When Treating Plaque Psoriasis (clinicaltrials.gov) - Dec 15, 2015
P=N/A, N=899, Active, not recruiting, Sponsor: Amgen
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- nystatin oral / Generic mfg.
Trial completion, Enrollment change: The Use of Probiotics in Patients With Symptomatic Oral Lichen Planus (clinicaltrials.gov) - Dec 12, 2015
P=N/A, N=25, Completed, Sponsor: University of Copenhagen
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | N=120 --> 25